SAN FRANCISCOâ€”Two cancer immunotherapy drugs being developed by Bristol-Myers Squibb Co. and Merck & Co. proved remarkably effective against the blood cancer Hodgkin lymphoma in two small, separate studies, researchers said Saturday, adding to growing evidence of the potential for enlisting the immune system in the fight against a wide range of tumors.. The drugs, nivolumab from Bristol-Myers and Keytruda from Merck, work by releasing a natural immune system brake known as PD-1 that some tumors are able to use to evade an...
  